Investor Presentaiton

Trice-Company Overview COMPANY OVERVIEW Market Segment: Headquarters: CEO: . Medical Device Malvern, PA Mark Foster Pioneering disposable cameras and instruments that enable faster diagnostics and shift of low-risk procedures to the office and surgery center settings • Trice Medical's FDA-approved 510(k)-cleared device, mi-eye 2, is a disposable, handheld 2.2mm arthroscope, consisting of a needle with an integrated camera and a light source designed for in-office diagnostics Camera and ultrasound (mi-Ultra) products help physicians with real-time analysis, faster treatment, and schedule patients for surgery immediately Endoscopic Carpal Tunnel Release (ECTR) kit includes surgical instruments and a mi-eye 2; kit allows physicians to perform procedures in the office • • IP for other indications including neurosurgery, ob-gyn, respiratory, ENT and veterinary Origin: Capital: Ownership: Financing Rounds: Other Investors: Trice Medical SUMMARY July 2014 $11.8M 17% Primary / 14% Fully Diluted Series B, Series C Charter Capital, BioStar Ventures, HealthQuest Capital, Michigan Employees Retirement System, Smith & Nephew Board Member: Gary Kurtzman (Chair) REVENUE MODEL • • • • THESIS mi-Eye addressable market (U.S.) is more than 8 million orthopedic-focused MRI exams which are conducted each year. Positive economics for payers and providers Carpal tunnel represents a growing market size with over 600K performed annually with a favorable market trend towards endoscopic (versus open) procedures Strong proprietary position provides the ability to enter additional verticals and partner/license. Expanding with recent acquisition of Tenex Health Trice sells the mi-eye cameras, ECTR kits, mi-Ultra, and companion tablets to physicians on a per-unit basis. Trice also licenses its IP and services out to select large medtech firms for use cases Trice does not plan on pursuing independently. COMPETITORS Arthrex, Karl Storz, Smith & Nephew, Stryker, Depuy Synthes, CONMED, Biomet-Zimmer, J&J G www.safeguard.com © 2021 Safeguard Scientifics, Inc. All rights reserved. SFE LISTED NYSE 24 24

View entire presentation